Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis

BACKGROUND AND OBJECTIVES: To report safety of ocrelizumab (OCR) up to 7 years in patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) enrolled in clinical trials or treated in real-world postmarketing settings. METHODS: Safety analyses are based on inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauser, Stephen L., Kappos, Ludwig, Montalban, Xavier, Craveiro, Licinio, Chognot, Cathy, Hughes, Richard, Koendgen, Harold, Pasquarelli, Noemi, Pradhan, Ashish, Prajapati, Kalpesh, Wolinsky, Jerry S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548959/
https://www.ncbi.nlm.nih.gov/pubmed/34475123
http://dx.doi.org/10.1212/WNL.0000000000012700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548959/
https://www.ncbi.nlm.nih.gov/pubmed/34475123
http://dx.doi.org/10.1212/WNL.0000000000012700

Ejemplares similares